Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Amgen to acquire Horizon for $26 billion as Sanofi drops bid - report

Published 12/12/2022, 05:17 AM
Updated 12/12/2022, 05:26 AM
© Reuters.  Amgen (AMGN) to acquire Horizon (HZNP) for $26 billion as Sanofi (SNY) drops bid - report
SASY
-
AMGN
-
JNJ
-
HZNP
-

By Senad Karaahmetovic

Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the deal at about $26 billion.

If completed, Horizon would become Amgen’s largest-ever acquisition. The deal could be announced as soon as this week, although the talks could still fall apart, according to Bloomberg.

The Wall Street Journal reported first that Amgen is in advanced talks to buy Horizon for “well over $20 billion.”

Horizon accepted the bid from Amgen after French giant Sanofi SA (EPA:SASY) said it won’t proceed with an offer due to a high price. Johnson & Johnson (NYSE:JNJ) also pulled out from the race earlier this month.

Amgen’s $116.5 per share bid for Horizon represents a 20% premium to the firm’s closing price on Friday. Horizon shares soared over 27% on November 29 on the report that several large companies are discussing a takeover deal. The agreed price represents a 48% premium relative to HZNP’s closing price on November 28.

For Mizuho analysts, the takeover makes “strategic sense” due to two key reasons. First, Amgen’s Otezla and Enbrel are facing competition from Sotyktu and HZNP's portfolio “could help fill that gap as a growth driver for AMGN.”

Second, they argue, that an HZNP takeover “could potentially help Amgen manage its tax burden going forward."

“In 2014 HZNP acquired Vidara Therapeutics International, which moved Horizon to Ireland and reduced its tax bill substantially. AMGN is facing potentially higher taxes due to ongoing issues with its Puerto Rico facility and a deal with HZNP could perhaps help to mitigate this issue, in our view,” the analysts added.

Oppenheimer analysts added that the two companies have a complementary autoimmune pipeline. On the valuation, the analysts said earlier that the reasonable price for HZNP would be around $120 per share.

HZNP stock is up 14% to $111.00 per share in pre-open Monday while Amgen shares are down 0.8%.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.